Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18471537 | 0.83 | CNR2 (0.35) | AOC3EPHA2EPHB4CNR2 | |
| SCHEMBL20365263 | 0.80 | AOC3 (0.38) | AOC3CNR2 | |
| SCHEMBL91618 | 0.80 | AOC3 (0.32) | AOC3CNR2 | |
| SCHEMBL21325031 | 0.79 | CXCR3 (0.31) | AOC3KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL2869276 | 0.78 | AOC3 (0.31) | AOC3KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL2869278 | 0.78 | NOTUM (0.40) | AOC3CNR2 | |
| SCHEMBL478959 | 0.78 | CNR2 (0.33) | AOC3KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL10058001 | 0.77 | ALDH1A1 (0.42) | AOC3KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL21324892 | 0.76 | NPC1 (0.45) | CNR2NPC1HTTRAB9ASMN1; SMN2 | |
| SCHEMBL1912688 | 0.76 | L3MBTL1 (0.31) | NPC1HTTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20150266856-A1 | RORGamma Modulators | EXELIXIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120115895-A1 | TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20080214589-A1 | Thrombin Inhibiting 2,4-Dioxo-3,4-Dihydropyrimidine Derivatives | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | US | disclosed |
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| US-20070099962-A1 | 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266856-A1 | RORGamma Modulators | RORB, RORA, RORC | AOC3 4037/4885KDM4E 3043/4885ALDH1A1 1877/4885 |
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | AOC3 3744/4885KDM4E 2426/4885ALDH1A1 1669/4885 |
| US-20080214589-A1 | Thrombin Inhibiting 2,4-Dioxo-3,4-Dihydropyrimidine Derivatives | F2, PLAT, F2R | AOC3 2375/4885KDM4E 3099/4885ALDH1A1 1405/4885 |
| US-20070099962-A1 | 5,6-Dihydropyrin-2-one compounds useful as inhibitors of thrombin | F2, SERPINC1, SERPINE1 | AOC3 2716/4885KDM4E 4532/4885ALDH1A1 1015/4885 |
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | AOC3 2054/4885KDM4E 2691/4885ALDH1A1 1813/4885 |
| US-20120115895-A1 | TRICYCLIC INDOLE-DERIVED SPIRO DERIVATIVES AS CRTH2 MODULATORS | HRH2, HRH1, LTC4S | AOC3 2678/4885KDM4E 4455/4885ALDH1A1 650/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | AOC3 4481/4885KDM4E 1058/4885ALDH1A1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.